Free Trial

BIOLASE (BIOL) Competitors

BIOLASE logo
$0.01 0.00 (-16.69%)
As of 03/26/2025

BIOL vs. NVIVQ, LGMK, DYNT, CUTR, SONX, GMVDF, SDCCQ, VRAYQ, AHPI, and NMRD

Should you be buying BIOLASE stock or one of its competitors? The main competitors of BIOLASE include Invivo Therapeutics (NVIVQ), LogicMark (LGMK), Dynatronics (DYNT), Cutera (CUTR), Sonendo (SONX), G Medical Innovations (GMVDF), SmileDirectClub (SDCCQ), ViewRay (VRAYQ), Allied Healthcare Products (AHPI), and Nemaura Medical (NMRD). These companies are all part of the "medical equipment" industry.

BIOLASE vs.

BIOLASE (NASDAQ:BIOL) and Invivo Therapeutics (NASDAQ:NVIVQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, community ranking, profitability, valuation and analyst recommendations.

BIOLASE presently has a consensus price target of $1.20, indicating a potential upside of 9,515.38%. Given BIOLASE's stronger consensus rating and higher possible upside, research analysts clearly believe BIOLASE is more favorable than Invivo Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BIOLASE
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Invivo Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Invivo Therapeutics has lower revenue, but higher earnings than BIOLASE.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BIOLASE$48.83M0.01-$20.63M-$14.940.00
Invivo TherapeuticsN/AN/A-$10.49MN/AN/A

BIOLASE received 292 more outperform votes than Invivo Therapeutics when rated by MarketBeat users.

CompanyUnderperformOutperform
BIOLASEOutperform Votes
292
51.59%
Underperform Votes
274
48.41%
Invivo TherapeuticsN/AN/A

In the previous week, BIOLASE had 2 more articles in the media than Invivo Therapeutics. MarketBeat recorded 2 mentions for BIOLASE and 0 mentions for Invivo Therapeutics. BIOLASE's average media sentiment score of 0.00 equaled Invivo Therapeutics'average media sentiment score.

Company Overall Sentiment
BIOLASE Neutral
Invivo Therapeutics Neutral

8.8% of BIOLASE shares are owned by institutional investors. Comparatively, 12.3% of Invivo Therapeutics shares are owned by institutional investors. 0.3% of BIOLASE shares are owned by company insiders. Comparatively, 2.5% of Invivo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Invivo Therapeutics has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Invivo Therapeutics' return on equity of 0.00% beat BIOLASE's return on equity.

Company Net Margins Return on Equity Return on Assets
BIOLASE-41.65% -1,782.73% -55.31%
Invivo Therapeutics N/A N/A N/A

BIOLASE has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Invivo Therapeutics has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.

Summary

BIOLASE beats Invivo Therapeutics on 7 of the 13 factors compared between the two stocks.

Remove Ads
Get BIOLASE News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIOL vs. The Competition

MetricBIOLASEDental equipment & supplies IndustryMedical SectorNASDAQ Exchange
Market Cap$417,000.00$3.64B$5.64B$8.06B
Dividend YieldN/A2.17%4.57%4.01%
P/E Ratio0.0036.2123.1319.03
Price / Sales0.011.39383.8993.17
Price / CashN/A6.5738.1634.64
Price / Book-0.180.716.944.33
Net Income-$20.63M-$146.24M$3.20B$247.06M
7 Day PerformanceN/A0.85%-2.33%-0.37%
1 Month PerformanceN/A-8.15%2.84%-3.85%
1 Year PerformanceN/A224.50%10.74%1.27%

BIOLASE Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIOL
BIOLASE
0.7793 of 5 stars
$0.01
-16.7%
$1.20
+9,515.4%
-93.5%$417,000.00$48.83M0.00160Analyst Forecast
News Coverage
NVIVQ
Invivo Therapeutics
N/A$0.37
flat
N/AN/A$1.15MN/A0.006High Trading Volume
LGMK
LogicMark
0.4271 of 5 stars
$0.18
+3.7%
N/A-99.8%$919,000.00$10.08M0.0020Short Interest ↑
Positive News
Gap Down
High Trading Volume
DYNT
Dynatronics
N/A$0.10
-13.2%
N/A-77.0%$899,000.00$33.60M-0.12200Analyst Forecast
Gap Down
CUTR
Cutera
2.0131 of 5 stars
$0.04
-63.9%
$3.00
+7,592.3%
-97.2%$787,000.00$155.21M-0.01460Analyst Forecast
Gap Down
High Trading Volume
SONX
Sonendo
N/A$1.81
+1.7%
N/A+1,503.8%$773,000.00$44.40M-0.03250News Coverage
GMVDF
G Medical Innovations
N/A$0.00
flat
N/A-98.7%$52,000.00$4.42M0.0072
SDCCQ
SmileDirectClub
N/A$0.00
flat
N/A-90.0%$40,000.00$470.74M0.002,700
VRAYQ
ViewRay
N/AN/AN/AN/A$18,000.00$102.21M0.00300Gap Up
High Trading Volume
AHPI
Allied Healthcare Products
N/AN/AN/AN/A$16,000.00$27.05M0.00150Gap Up
NMRD
Nemaura Medical
N/A$0.00
flat
N/A-99.8%$8,000.00$3,017.000.0040
Remove Ads

Related Companies and Tools


This page (NASDAQ:BIOL) was last updated on 3/28/2025 by MarketBeat.com Staff
From Our Partners